Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
(Date:10/31/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights Conference ... ET / 8:30 a.m. PTWhere: , www.isispharm.com ... onto our website listed above. If you are unable ... the webcast will be available for a limited time ...
(Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
... many, clinical studies are few, NEW YORK, ... revealed that a limited amount of clinical research ... anti-aging,products. The study is published in the July/August ... peer-reviewed journal of the,American Society for Aesthetic Plastic ...
... (Amex: IMM ) commented today on a ... group of researchers at the National Cancer Institute,on ... enzyme involved in the DNA,repair process (see Note ... proprietary, orally bioavailable prodrug, pafuramidine. Of,interest is furamidine,s ...
Cached Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3
(Date:10/31/2014)... Oct. 30, 2014 (HealthDay News) -- A comparison of ... surgery found that laparoscopic gastric bypass helped patients shed ... a higher risk of short-term complications and long-term hospitalizations. ... the small intestine, so your body does not absorb ... the National Institutes of Health. Gastric banding is a ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, ... the risk of broken bones and injured joints, a new study ... among 7 percent of people who had an eczema flare-up in ... and 0.6 percent had an injury that caused a limitation of ... skin condition had more than double the risk of having had ...
(Date:10/30/2014)... could one day provide new treatments for injuries and ... ligaments. , Cartilage, for example, is a hard material ... to work smoothly. UC Davis biomedical engineers, exploring ways ... strong outside the body, report new developments this week ... of Sciences . , "The problem with engineered tissue ...
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... NC (PRWEB) October 30, 2014 Don ... commercial, and health insurance plans for North Carolina residents, ... satellite office in Burlington’s Holly Hill Mall. The new ... with agents already helping customers through all facets of ... purchase. , Allred Insurance spokesman Scott Allred couldn’t be ...
Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
... Demonstrate Deepening Relationship , Between Edwards and Primary Sponsor ... off its first year as primary sponsor of Carl ... big way with the launch of its latest television ... to air during the national broadcast of the Feb. ...
... Prevent Preterm BirthWHITE PLAINS, N.Y., Feb. 11 ... may cause preterm labor in some women, investigate ... contractions and an early birth, and look at ... environmental risk factors for prematurity.The work of seven ...
... and St George,s, University of London measured recent exposure to ... British Regional Heart Study by measuring the levels of cotinine ... time points 20 years apart. A blood cotinine level above ... of a heart attack (2), and other studies have suggested ...
... Results of a recent study conducted by researchers ... show that cognitive functioning abilities drop as average blood ... , The study appears in this month,s issue of ... Diabetes (MIND) study, a sub-study of the Action to ...
... French . , Montreal, February 11th, 2009 ... the nutrients the tumours receive through the blood. The team ... McGill University Health Centre (MUHC) at the Montreal Children,s Hospital, ... a new mechanism that tumours use to stimulate the growth ...
... world,s first phase one FDA-approved clinical trial using adult ... conducted by a team of University of Louisville ... with advanced heart disease who already are undergoing bypass ... trial, which uses adult stem cells taken from the ...
Cached Medicine News:Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 2Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 3Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 4Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 2Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: